AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 CytokineticsI-MabCannTrustGossamer BioAmphastar Pharmaceuticals
SymbolNASDAQ:CYTKNASDAQ:IMABOTCMKTS:CNTTFNASDAQ:GOSSNASDAQ:AMPH
Price Information
Current Price$21.11$24.92N/A$12.10$18.84
52 Week RangeBuyBuyN/ABuyBuy
Beat the Market™ Rank
Overall Score1.81.01.11.41.9
Analysis Score4.51.50.03.53.3
Community Score3.53.62.62.42.7
Dividend Score0.00.00.00.00.0
Ownership Score1.00.00.01.01.0
Earnings & Valuation Score0.00.03.10.02.5
Analyst Ratings
Consensus RecommendationBuyBuyN/ABuyBuy
Consensus Price Target$26.43$17.34N/A$29.29$24.33
% Upside from Price Target25.19% upside-30.42% downsideN/A142.03% upside29.19% upside
Trade Information
Market Cap$1.24 billion$1.42 billion$67.40 million$806.26 million$880.11 million
Beta1.41N/A4.521.141.12
Average Volume931,06693,269N/A531,076282,793
Sales & Book Value
Annual Revenue$26.87 million$4.31 million$15.96 millionN/A$322.36 million
Price / Sales46.72329.920.00N/A2.70
CashflowN/AN/AN/AN/A$0.77 per share
Price / CashN/AN/AN/AN/A24.36
Book Value($0.19) per shareN/AN/A$5.34 per share$9.11 per share
Price / Book-111.11∞NaNN/A2.07
Profitability
Net Income$-121,690,000.00N/AN/A$-180,310,000.00$48.94 million
EPS($2.11)($28.90)$0.07($3.29)$0.36
Trailing P/E RatioN/AN/A9.11N/A17.94
Forward P/E RatioN/AN/A0.00N/A15.57
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-592.61%N/AN/AN/A15.90%
Return on Equity (ROE)-10,351.99%N/AN/A-53.83%4.99%
Return on Assets (ROA)-56.54%N/AN/A-45.47%3.65%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.12%0.12%
Current Ratio10.89%N/AN/A12.53%2.96%
Quick Ratio10.89%N/AN/A12.53%1.67%
Ownership Information
Institutional Ownership Percentage93.71%8.15%0.08%58.13%51.79%
Insider Ownership Percentage6.40%N/AN/A23.30%29.80%
Miscellaneous
Employees130185N/A1182,027
Shares Outstanding59.47 million57.06 million105.64 million66.36 million46.20 million
Next Earnings Date8/13/2020 (Estimated)N/AN/A8/13/2020 (Estimated)8/5/2020 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableOptionable
Comparison Ideas:
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.